

## DAFTAR PUSTAKA

1. Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options. *Front Microbiol* 2019;10:80
2. Aslam B, Rasool M, Muzammil S, Siddique AB, Nawaz Z, Shafique M. Carbapenem Resistance : Mechanisms and Drivers of Global Menace. IntechOpen; 2020.
3. Abdeta A, Bitew A, Fentaw S, Tsige E, Assefa D, Lejisa T, et al. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens. *PLoS One*. 2021;16(12):e0256556.
4. Macareño-Castro J, Solano-Salazar A, Dong LT, Mohiuddin M, Espinoza JL. Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review. *Journal of Infection*. 2022 ;84(6):749–59.
5. Carrara E, Savoldi A, Piddock LJV, Franceschi F, Ellis S, Sharland M, et al. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations. *Clinical Microbiology and Infection*. 2022 Jan;28(1):66–72.
6. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention (U.S.); 2019.
7. WHO. WHO Bacterial Priority List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024.
8. Sader HS, Carvalhaes CG, Arends SJR, Castanheira M, Mendes RE. Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. *Journal of Antimicrobial Chemotherapy*. 2021;76(3):659–66.
9. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. Geneva: World Health Organization; 2022.
10. Malchione MD, Torres LM, Hartley DM, Koch M, Goodman JL. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges. *International Journal of Antimicrobial Agents*. 2019; 54(4):381–99.
11. Komite Pengendalian Resistensi Antibiotik. Antibiogram dan Pola Kuman RSUP Dr. M. Djamil Padang Tahun 2023.
12. Jean SS, Harnod D, Hsueh PR. Global Threat of Carbapenem-Resistant Gram-Negative Bacteria. *Front Cell Infect Microbiol*. 2022;12:823684.
13. Queenan AM, Bush K. Carbapenemases: the Versatile  $\beta$ -Lactamases. *Clin Microbiol Rev*. 2007; 20(3):440–58.
14. Lee CS, Doi Y. Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens. *Infect Chemother*. 2014 ;46(3):149.
15. Monteiro J, Widen RH, Pignatari ACC, Kubasek C, Silbert S. Rapid detection

- of carbapenemase genes by multiplex real-time PCR. *Journal of Antimicrobial Chemotherapy*. 2012 ;67(4):906–9.
16. Nordmann P, Poirel L. Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria. *Clinical Infectious Diseases*. 2019; 69: S521–8.
  17. Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, et al. Carbapenemase-Producing Organisms: A Global Scourge. *Clinical Infectious Diseases*. 2018;66(8):1290–7.
  18. Sawa T, Kooguchi K, Moriyama K. Molecular diversity of extended-spectrum  $\beta$ -lactamases and carbapenemases, and antimicrobial resistance. *J intensive care*. 2020;8(1):13.
  19. Eichenberger EM, Thaden JT. Epidemiology and Mechanisms of Resistance of Extensively Drug Resistant Gram-Negative Bacteria. *Antibiotics*. 2019;8(2):37.
  20. Van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. *Virulence*. 2017;8(4):460–9.
  21. Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. *The Journal of Infectious Diseases*. 2017;1:S28–36.
  22. Suwantararat N, Carroll KC. Epidemiology and molecular characterization of multidrug-resistant Gram-negative bacteria in Southeast Asia. *Antimicrob Resist Infect Control*. 2016;5(1):15.
  23. Saharman YR, Karuniawati A, Sedono R, Aditjaningsih D, Goessens WHF, Klaassen CHW, et al. Clinical impact of endemic NDM-producing *Klebsiella pneumoniae* in intensive care units of the national referral hospital in Jakarta, Indonesia. *Antimicrob Resist Infect Control*. 2020;9(1):61. 201820(6):13.
  24. Kuntaman K, Shigemura K, Osawa K, Kitagawa K, Sato K, Yamada N, et al. Occurrence and characterization of carbapenem-resistant Gram-negative bacilli: A collaborative study of antibiotic-resistant bacteria between Indonesia and Japan. *Int J of Urology*. 2018;25(11):966–72.
  25. Karuniawati A, Saharman YR, Lestari DC. Detection of carbapenemase encoding genes in Enterobacteriaceae, *Pseudomonas aeruginosa*, and *Acinetobacter baumannii* isolated from patients at Intensive Care Unit Cipto Mangunkusumo Hospital in 2011. *Acta Med Indones*. 2013 Apr;45(2):101–6.
  26. Barry KE, Wailan AM, Sheppard AE, Crook D, Vegesana K, Stoesser N, et al. Don't overlook the little guy: An evaluation of the frequency of small plasmids co-conjugating with larger carbapenemase gene containing plasmids. *Plasmid*. 2019;103:1–8.
  27. Ghasemnejad A, Doudi M, Amirmozafari N. The role of the bla KPC gene in antimicrobial resistance of *Klebsiella pneumoniae*. *IJM*. 2019;11(4):288.
  28. Porreca AM, Sullivan KV, Gallagher JC. The Epidemiology, Evolution, and Treatment of KPC-Producing Organisms. *Curr Infect Dis Rep*. 2018;20(6):13.
  29. Van Duin D, Arias CA, Komarow L, Chen L, Hanson BM, Weston G, et al. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. *The Lancet Infectious Diseases*. 2020;20(6):731–41.

30. Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant *Enterobacteriaceae* Bacteremia. *Clinical Infectious Diseases*. 2017;64(3):257–64.
31. Hammoudi Halat D, Ayoub Moubareck C. The Current Burden of Carbapenemases: Review of Significant Properties and Dissemination among Gram-Negative Bacteria. *Antibiotics*. 2020;9(4):186.
32. Aruhomukama D, Najjuka CF, Kajumbula H, Okee M, Mboowa G, Sserwadda I, et al. blaVIM- and blaOXA-mediated carbapenem resistance among *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates from the Mulago hospital intensive care unit in Kampala, Uganda. *BMC Infect Dis*. 2019;19(1):853.
33. Dong H, Li Y, Cheng J, Xia Z, Liu W, Yan T, et al. Genomic Epidemiology Insights on NDM-Producing Pathogens Revealed the Pivotal Role of Plasmids on *bla*<sub>NDM</sub> Transmission. Martin RM, ed. *Microbiol Spectr*. 2022;29;10(2):e02156-21.
34. Yang C, Jiang S, Wei C, Li C, Wang J, Li X, et al. Mechanism for transmission and pathogenesis of carbapenem-resistant *Enterobacterales* harboring the carbapenemase IMP and clinical countermeasures. She RC, editor. *Microbiol Spectr*. 2024;e02318-23.
35. Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. NDM Metallo- $\beta$ -Lactamases and Their Bacterial Producers in Health Care Settings. *Clin Microbiol Rev*. 2019;32(2):e00115-18.
36. Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, et al. *In Vitro* Activity of Imipenem against Carbapenemase-Positive *Enterobacteriaceae* Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014. Munson E, editor. *J Clin Microbiol*. 2017;55(6):1638–49.
37. Pudpong K, Pattharachayakul S, Santimaleeworagun W, Nwabor OF, Laohaprertthisan V, Hortiwakul T, et al. Association Between Types of Carbapenemase and Clinical Outcomes of Infection Due to Carbapenem Resistance *Enterobacterales*. *IDR*. 2022;15:3025–37.
38. Hansen GT. Continuous Evolution: Perspective on the Epidemiology of Carbapenemase Resistance Among *Enterobacterales* and Other Gram-Negative Bacteria. *Infect Dis Ther*. 2021;10(1):75–92.
39. Paveenkittiporn W, Lyman M, Biedron C, Chea N, Bunthi C, Kolwaite A, et al. Molecular epidemiology of carbapenem-resistant *Enterobacterales* in Thailand, 2016–2018. *Antimicrob Resist Infect Control*. 2021;10(1):88.
40. Tunyong W, Arsheewa W, Santajit S, Kong-ngoen T, Pumirat P, Sookrung N, et al. Antibiotic Resistance Genes Among Carbapenem-resistant *Enterobacterales* (CRE) Isolates of Prapokklao Hospital, Chanthaburi Province, Thailand. *IDR*. 2021 14:3485–94.
41. Falcone M, Tiseo G, Carbonara S, Marino A, Di Caprio G, Carretta A, et al. Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide

- Study in Italy (ALARICO Network). *Clinical Infectious Diseases* [Internet]. 2023 Jun 16;76(12):2059–69.
42. Mariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. *Int J App Basic Med Res*. 2017;7(1):32.
  43. Papadimitriou-Olivgeris M, Fligou F, Bartzavali C, Zotou A, Spyropoulou A, Koutsileou K, et al. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream infection in critically ill patients: risk factors and predictors of mortality. *Eur J Clin Microbiol Infect Dis*. 2017;36(7):1125–31.
  44. Snyder BM, Montague BT, Anandan S, Madabhushi AG, Pragasam AK, Verghese VP, et al. Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo- $\beta$ -lactamase (NDM-1) producing *Enterobacteriaceae*. *Epidemiol Infect*. 2019;147:e137.
  45. Jamal WY, Albert MJ, Rotimi VO. High Prevalence of New Delhi Metallo- $\beta$ -Lactamase-1 (NDM-1) Producers among Carbapenem-Resistant Enterobacteriaceae in Kuwait. Galdiero M, editor. *PLoS ONE*. 2016;11(3):e0152638.
  46. Fortunato G, Vaz-Moreira I, Gajic I, Manaia CM. Insight into phylogenomic bias of bla or bla dissemination amongst carbapenem-resistant *Pseudomonas aeruginosa*. *International Journal of Antimicrobial Agents* [Internet]. 2023 May;61(5):106788.
  47. Bush K, Bradford PA. Epidemiology of  $\beta$ -Lactamase-Producing Pathogens. *Clin Microbiol Rev*. 2020;33(2):e00047-19.
  48. Li X, Mu X, Chen F, Lu X, He J, Zheng Y, et al. Characterization of Three Novel IMP Metallo- $\beta$ -Lactamases, IMP-89, IMP-91, and IMP-96, and Diverse bla<sub>IMP</sub>-Carrying Accessory Genetic Elements from Chinese Clinical Isolates. Schaufler K, editor. *Microbiol Spectr*. 2023;11(3):e04986-22. 49.
  49. Pongchaikul P, Mongkolsuk P. Comprehensive Analysis of Imipenemase (IMP)-Type Metallo- $\beta$ -Lactamase: A Global Distribution Threatening Asia. *Antibiotics*. 2022;11(2):236.
  50. Sabrina T, Rivani E, Patricia V. Analisis Gen Blavim, Blandm dan Blaimp Carbapenemase dengan Alat Otomatis Vitek-2 dan Metode Polymerase Chain Reaction (PCR) pada Isolat Bakteri Enterobacteriaceae di RSUP Dr. Moh. Hoesin Palembang. 2018;5(2).
  51. Iovleva A, Doi Y. Carbapenem-Resistant Enterobacteriaceae. *Clinics in Laboratory Medicine*. 2017;37(2):303–15.
  52. Massella E, Giacometti F, Bonilauri P, Reid CJ, Djordjevic SP, Merialdi G, et al. Antimicrobial Resistance Profile and ExPEC Virulence Potential in Commensal *Escherichia coli* of Multiple Sources. *Antibiotics*. 2021;10(4):351.
  53. Corbella L, Fernández-Ruiz M, Ruiz-Ruigómez M, Rodríguez-Goncer I, Silva JT, Hernández-Jiménez P, et al. Prognostic factors of OXA-48 carbapenemase-producing *Klebsiella pneumoniae* infection in a tertiary-care Spanish hospital: A retrospective single-center cohort study. *International Journal of Infectious Diseases*. 2022;119:59–68.
  54. Barlow M, Hall BG. Phylogenetic Analysis Shows That the OXA  $\beta$ -Lactamase

- Genes Have Been on Plasmids for Millions of Years. *Journal of Molecular Evolution*. 2002;55(3):314–21.
55. Palacios-Baena ZR, Giannella M, Manissero D, Rodríguez-Baño J, Viale P, Lopes S, et al. Risk factors for carbapenem-resistant Gram-negative bacterial infections: a systematic review. *Clinical Microbiology and Infection*. 2021;27(2):228–35.
  56. Pano-Pardo JR, Ruiz-Carrascoso G, Navarro-San Francisco C, Gomez-Gil R, Mora-Rillo M, Romero-Gomez MP, et al. Infections caused by OXA-48-producing *Klebsiella pneumoniae* in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. *Journal of Antimicrobial Chemotherapy*. 2013;68(1):89–96.
  57. Zhu Y, Xiao T, Wang Y, Yang K, Zhou Y, Luo Q, et al. Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae. *IDR*. 2021;14:5385–93.
  58. López Montesinos I, Carot-Coll A, Montero MM, Sorli Redó L, Siverio-Parès A, Esteban-Cucó S, et al. A case–control study of the clinical and economic impact of infections caused by Carbapenemase-producing Enterobacterales (CPE). *Infection*. 2024.
  59. Imai S, Inoue N, Nagai H. Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan. *BMC Infect Dis*. 2022;22(1):581.
  60. Yungyuen T, Chatsuwan T, Plongla R, Kanthawong S, Yordpratum U, Voravuthikunchai SP, et al. Nationwide Surveillance and Molecular Characterization of Critically Drug-Resistant Gram-Negative Bacteria: Results of the Research University Network Thailand Study. *Antimicrob Agents Chemother*. 2021;65(9):e00675-21.
  61. Saharman YR, Karuniawati A, Sedono R, Aditjaningsih D, Sudarmono P, Goessens WHF, et al. Endemic carbapenem-nonsusceptible *Acinetobacter baumannii*-calcoaceticus complex in intensive care units of the national referral hospital in Jakarta, Indonesia. *Antimicrob Resist Infect Control*. 2018;7(1):5.
  62. Fadrian F, Decroli E, Ahmad A, Kam A, Muharramah DH, Pradana G, et al. In-hospital mortality and its determinant factors among patients with sepsis. *Univ Med*. 2025;44(1):3–15.
  63. Ing A, Humphries R. The Genotype—Phenotype Conundrum for Antimicrobial Susceptibility Testing. *Clinical Chemistry*. 2023;69(4):316–8.
  64. Hatrongjit R, Chopjitt P, Boueroy P, Kerdsin A. Multiplex PCR Detection of Common Carbapenemase Genes and Identification of Clinically Relevant *Escherichia coli* and *Klebsiella pneumoniae* Complex. *Antibiotics*. 2022;12(1):76.
  65. Munir P, Zeshan B, Saleem MA, Qureshi M, Riaz S. Correlation of blaNDM to Antibiotic Resistance Patterns in *Klebsiella pneumoniae* Isolates from Tertiary Care Hospital in Lahore, Pakistan. 2019; 1(2):03-09.
  66. Tafreshi N, Babaeekhou L, Ghane M. Antibiotic resistance pattern of *Acinetobacter baumannii* from burns patients: increase in prevalence of blaOXA-24-like and blaOXA-58-like genes. *IJM*. 2019;11(6):502

67. Gatya Al-Mayahie SM, Al-Guranie DRT, Hussein AA, Bachai ZA. Prevalence of common carbapenemase genes and multidrug resistance among uropathogenic *Escherichia coli* phylogroup B2 isolates from outpatients in Wasit Province/ Iraq. *Alghammal AM, editor. PLoS ONE*. 2022; 25;17(1):e0262984.
68. Mulla S, Charan J, Rajdev S. Antibiotic sensitivity pattern in blaNDM-1-positive and carbapenemase-producing Enterobacteriaceae. *Int J App Basic Med Res*. 2016 ;6(1):14.
69. Li Y, Xie C, Zhang Z, Liu J, Chang H, Liu Y, et al. Molecular epidemiology and antimicrobial resistance profiles of *Klebsiella pneumoniae* isolates from hospitalized patients in different regions of China. *Front Cell Infect Microbiol*. 2024;14:1380678.
70. Nguyen M, Joshi SG. Carbapenem resistance in *Acinetobacter baumannii* , and their importance in hospital-acquired infections: a scientific review. *J Appl Microbiol*. 2021;131(6):2715–38.
71. Hawkey PM, Livermore DM. Carbapenem antibiotics for serious infections. *BMJ*. 2012;344:e3236–e3236.
72. Aurilio C, Sansone P, Barbarisi M, Pota V, Giaccari LG, Coppolino F, et al. Mechanisms of Action of Carbapenem Resistance. *Antibiotics*. 2022;11(3):421.
73. De Rosa M, Verdino A, Soriente A, Marabotti A. The Odd Couple(s): An Overview of Beta-Lactam Antibiotics Bearing More Than One Pharmacophoric Group. *IJMS*. 2021 Jan 9;22(2):617.
74. Carrara E, Savoldi A, Piddock LJV, Franceschi F, Ellis S, Sharland M, et al. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations. *Clinical Microbiology and Infection*. 2022;28(1):66–72.
75. Lima EM, Cid PA, Beck DS, Pinheiro LHZ, Tonhá JPS, Alves MZO, et al. Predictive factors for sepsis by carbapenem resistant Gram-negative bacilli in adult critical patients in Rio de Janeiro: a case-case-control design in a prospective cohort study. *Antimicrob Resist Infect Control*. 2020;9(1):132.
76. Tilahun M, Kassa Y, Gedefie A, Belete MA. Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review. *IDR*. 2021;14:4363–74.
77. Chen X, Zhou M, Yan Q, Jian Z, Liu W, Li H. Risk factors for CARBAPENEM-RESISTANT Enterobacterales infection among hospitalized patients with previous colonization. *Clinical Laboratory Analysis*. 2022;36(11):e24715.
78. Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, González-Costello J, et al. Extensively Drug-Resistant *Pseudomonas aeruginosa* Bacteremia in Solid Organ Transplant Recipients. *Transplantation*. 2015;99(3):616–22.
79. Pettigrew MM, Gent JF, Kong Y, Halpin AL, Pineles L, Harris AD, et al. Gastrointestinal Microbiota Disruption and Risk of Colonization With Carbapenem-resistant *Pseudomonas aeruginosa* in Intensive Care Unit Patients. *Clinical Infectious Diseases*. 2019 Aug 1;69(4):604–13.
80. Caliskan-Aydogan O, Alocilja EC. A Review of Carbapenem Resistance in

- Enterobacterales and Its Detection Techniques. *Microorganisms*. 2023;11(6):1491.
81. Read AF, Woods RJ. Antibiotic resistance management. *Evolution, Medicine, and Public Health*. 2014;2014(1):147–147.
  82. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P T*. 2015 Apr;40(4):277–83.
  83. Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threat. Centers for Disease Control and Prevention (U.S.)2023.
  84. Bartlett JG, Gilbert DN, Spellberg B. Seven Ways to Preserve the Miracle of Antibiotics. *Clinical Infectious Diseases*. 2013.;56(10):1445–50.
  85. Mmatli M, Mbelle NM, Maningi NE, Osei Sekyere J. Emerging Transcriptional and Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance in *Enterobacteriaceae* : a Systematic Review of Current Reports. Bulman Z, editor. *mSystems*. 2020.
  86. Weston N, Sharma P, Ricci V, Piddock LJV. Regulation of the AcrAB-TolC efflux pump in *Enterobacteriaceae*. *Research in Microbiology*. 2018;169(7–8):425–31.
  87. Jang S. AcrAB-TolC, a major efflux pump in Gram negative bacteria: toward understanding its operation mechanism. *BMB Rep*. 2023;56(6):326–34.
  88. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *The Lancet*.;399(10325):629–5589.
  89. Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the United States, 2019 [Internet]. Centers for Disease Control and Prevention (U.S.); 2019
  90. Pournaras S, Zarrilli R, Higgins PG, Tsioutis C. Editorial: Carbapenemase-Producing Organisms as Leading Cause of Hospital Infections. *Front Med*. 2021;8:775021.
  91. World Health Organization. Guidelines for the prevention and control of carbapenem-resistant *Enterobacteriaceae*, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in health care facilities. Geneva: World Health Organization; 2017. 74 p.
  92. Sheppard AE, Stoesser N, Wilson DJ, Sebra R, Kasarskis A, Anson LW, et al. Nested Russian Doll-Like Genetic Mobility Drives Rapid Dissemination of the Carbapenem Resistance Gene *bla*<sub>KPC</sub>. *Antimicrob Agents Chemother* [Internet]. 2016 Jun;60(6):3767–78. 93.
  93. Ma J, Song X, Li M, Yu Z, Cheng W, Yu Z, et al. Global spread of carbapenem-resistant *Enterobacteriaceae*: Epidemiological features, resistance mechanisms, detection and therapy. *Microbiological Research*. 2023;266:127249.
  94. Villegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing *Enterobacteriaceae*: A diagnostic, epidemiological and therapeutic challenge. *Infect*. 2019; 23(4):388.95. Ellington MJ, Davies F, Jauneikaite E, Hopkins KL, Turton JF, Adams G, et al. A Multispecies Cluster of GES-5 Carbapenemase-Producing *Enterobacterales* Linked by a Geographically

- Disseminated Plasmid. *Clinical Infectious Diseases*. 2020;71(10):2553–60.
95. Ellington MJ, Davies F, Jauneikaite E, Hopkins KL, Turton JF, Adams G, et al. A Multispecies Cluster of GES-5 Carbapenemase-Producing Enterobacterales Linked by a Geographically Disseminated Plasmid. *Clinical Infectious Diseases*. 2020;71(10):2553–60.
  96. Meenakshisundaram J. bla KPC gene Detection in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae in a Tertiary Care Hospital. *JCDR*. 2013;7(12):2736
  97. Mosca A, Miragliotta L, Del Prete R, Tzakis G, Dalfino L, Bruno F, et al. Rapid and sensitive detection of blaKPC gene in clinical isolates of *Klebsiella pneumoniae* by a molecular real-time assay. *SpringerPlus*. 2013;2(1):31.
  98. Baral R, Tuladhar R, Manandhar S, Singh A, Sherchan S. Detection of blaKPC gene among carbapenemase producing *Klebsiella pneumoniae* isolated from different clinical specimens at tertiary care hospital of Nepal. *BMC Microbiol*. 2024;24(1):144.
  99. Ribeiro PCS, Monteiro AS, Marques SG, Monteiro SG, Monteiro-Neto V, Coqueiro MMM, et al. Phenotypic and molecular detection of the blaKPC gene in clinical isolates from inpatients at hospitals in São Luis, MA, Brazil. *BMC Infect Dis*. 2016;16(1):737.
  100. Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, Yinnon AM, Assous MV. Mortality due to bla<sub>KPC</sub> *Klebsiella pneumoniae* bacteraemia. *J Antimicrob Chemother*. 2016;71(4):1083–7.
  101. Liu KS, Tong YS, Lee MT, Lin HY, Lu MC. Risk Factors of 30-Day All-Cause Mortality in Patients with Carbapenem-Resistant *Klebsiella pneumoniae* Bloodstream Infection. *JPM*. 2021;11(7):61102.
  102. Oka K, Matsumoto A, Tetsuka N, Morioka H, Iguchi M, Ishiguro N, et al. Clinical characteristics and treatment outcomes of carbapenem-resistant Enterobacterales infections in Japan. *Journal of Global Antimicrobial Resistance*. 2022 Jun;29:247–52.
  103. Seo H, Lee SC, Chung H, Ra SH, Sung H, Kim MN, et al. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. *International Journal of Antimicrobial Agents*. 2020;56(4):106126.
  104. Hong JS, Choi N, Kim SJ, Choi KH, Roh KH, Lee S. Molecular Characteristics of GES-Type Carbapenemase-Producing *Pseudomonas aeruginosa* Clinical Isolates from Long-Term Care Facilities and General Hospitals in South Korea. *Microbial Drug Resistance*. 2020;26(6):605–10.
  105. Boyd SE, Livermore DM, Hooper DC, Hope WW. Metallo- $\beta$ -Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline. *Antimicrob Agents Chemother*. 2020 Sep ;64(10):e00397-20.
  106. Gama JA, Kloos J, Johnsen PJ, Samuelson Ø. Host dependent maintenance of a blaNDM-1-encoding plasmid in clinical *Escherichia coli* isolates. *Sci Rep*. 2020;10(1):9332.
  107. Suzuki D, Sakurai A, Wakuda M, Suzuki M, Doi Y. Clinical and genomic characteristics of IMP-producing *Enterobacter cloacae* complex and *Klebsiella*

- pneumoniae*. Tamma PD, editor. Antimicrob Agents Chemother [Internet]. 2024 May 2;68(5):e01672-23
108. Hayakawa K, Nakano R, Hase R, Shimatani M, Kato H, Hasumi J, et al. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae. *Journal of Antimicrobial Chemotherapy*. 2020;75(3):697–708.
  109. Meng L, Liu Z, Liu C, Li C, Shen H, Cao X. The distribution characteristics of global blaOXA-carrying Klebsiella pneumoniae. *BMC Infect Dis*. 2023;23(1):182.
  110. Alizadeh N, Ahangarzadeh Rezaee M, Samadi Kafil H, Hasani A, Soroush Barhaghi MH, Milani M, et al. Evaluation of Resistance Mechanisms in Carbapenem-Resistant Enterobacteriaceae. *IDR*. 2020;13:1377–85.
  111. Joshi DN, Shenoy B, Mv B, Adhikary R, Shamarao S, Mahalingam A. Prevalence of Carbapenem-Resistant Enterobacteriaceae and the Genes Responsible for Carbapenemase Production in a Tertiary Care Hospital in South India. *EMJ*. 2023;12(3):462-67
  112. Berger S, Alauzet C, Aissa N, Hénard S, Rabaud C, Bonnet R, et al. Characterization of a New bla OXA-48 -Carrying Plasmid in Enterobacteriaceae. *Antimicrob Agents Chemother*. 2013;57(8):4064–7.
  113. Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. *Journal of Antimicrobial Chemotherapy*. 2006;57(3):373–83.T
  114. Tamma PD, Simner PJ. Phenotypic Detection of Carbapenemase-Producing Organisms from Clinical Isolates. Kraft CS, editor. *J Clin Microbiol*. 2018;56(11):e01140-18.
  115. Neves L, Marra AR, Camargo TZS, Dos Santos MC, Zulin F, Da Silva PC, et al. Correlation between mass and volume of collected blood with positivity of blood cultures. *BMC Res Notes*. 2015;8(1):383.
  116. Zornitzki L, Anuk L, Frydman S, Morag-Koren N, Zahler D, Freund O, et al. Rate and predictors of blood culture positivity after antibiotic administration: a prospective single-center study. *Infection*. 2024;52(2):483–90.
  117. Fabre V, Carroll KC, Cosgrove SE. Blood Culture Utilization in the Hospital Setting: a Call for Diagnostic Stewardship. Humphries RM, editor. *J Clin Microbiol*. 2022.;60(3):e01005-21.
  118. Romann L, Werlen L, Rommers N, Hermann A, Gisler I, Bassetti S, et al. Factors impacting the pre-analytical quality of blood cultures—Analysis at a tertiary medical center. Sambri V, editor. *PLoS ONE*. 2023;18(3):e0282918.
  119. Popova G, Boskovska K, Arnaudova-Danevska I, Smilevska-Spasova O, Jakovska T. Sputum Quality Assessment Regarding Sputum Culture for Diagnosing Lower Respiratory Tract Infections in Children. *Open Access Maced J Med Sci*. 2019;7(12):1926
  120. Pincus DH. Microbial Identification Using the Biomerioux Vitek 2 System in Encyclopedia of rapid Microbiological Methods. Bethesda: Parenteral Drug Association. 2006.1-32

121. Probst K, Nurjadi D, Heeg K, Frede AM, Dalpke AH, Boutin S. Molecular Detection of Carbapenemases in Enterobacterales: A Comparison of Real-Time Multiplex PCR and Whole-Genome Sequencing. *Antibiotics*. 2021;10(6):726.
122. Yoshioka N, Hagiya H, Deguchi M, Hamaguchi S, Kagita M, Nishi I, et al. Multiplex Real-Time PCR Assay for Six Major Carbapenemase Genes. *Pathogens*. 2021;10(3):276.
123. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801.
124. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. *Critical Care Medicine*. 2021;49(11):e1063–143.
125. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. *Intensive Care Med*. 2017 Mar ;43(3):304–77.
126. Sabino S, Soares S, Ramos F, Moretti M, Zavascki AP, Rigatto MH. A Cohort Study of the Impact of Carbapenem-Resistant *Enterobacteriaceae* Infections on Mortality of Patients Presenting with Sepsis. Bradford PA, editor. *mSphere*. 2019;4(2):e00052-19.
127. Al-Sunaidar KA, Aziz NA, Hassan Y, Jamshed S, Sekar M. Association of Multidrug Resistance Bacteria and Clinical Outcomes of Adult Patients with Sepsis in the Intensive Care Unit. *TropicalMed [Internet]*. 2022 Nov 9 [cited 2024;7(11):365
128. Kousouli E, Zarkotou O, Politi L, Polimeri K, Vrioni G, Themeli-Digalaki K, et al. Infection control interventions affected by resource shortages: impact on the incidence of bacteremias caused by carbapenem-resistant pathogens. *Eur J Clin Microbiol Infect Dis*. 2018;37(1):43–50.
129. Lemos EV, De La Hoz FP, Einarson TR, McGhan WF, Quevedo E, Castañeda C, et al. Carbapenem resistance and mortality in patients with *Acinetobacter baumannii* infection: systematic review and meta-analysis. *Clinical Microbiology and Infection*. 2014;20(5):416–23.
130. Falagas ME, Lourida P, Poulidakos P, Rafailidis PI, Tansarli GS. Antibiotic Treatment of Infections Due to Carbapenem-Resistant *Enterobacteriaceae*: Systematic Evaluation of the Available Evidence. *Antimicrob Agents Chemother*. 2014;58(2):654–63.
131. Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, et al. Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by *Acinetobacter baumannii* and *Pseudomonas aeruginosa*. *Open Forum Infectious Diseases*. 2017
132. Zhou R, Fang X, Zhang J, Zheng X, Shangguan S, Chen S, et al. Impact of carbapenem resistance on mortality in patients infected with *Enterobacteriaceae* : a systematic review and meta-analysis. *BMJ Open*. 2021.;11(12):e054971.
133. Kuloglu TO, Unuvar GK, Cevahir F, Kilic AU, Alp E. Risk factors and mortality rates of carbapenem-resistant Gram-negative bacterial infections in

- intensive care units. *Journal of Intensive Medicine*. 2024; 4(3):347-54
134. Montrucchio G, Costamagna A, Pierani T, Petitti A, Sales G, Pivetta E, et al. Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score. *Pathogens*. 2022;11(7):718.
  135. Wang M, Earley M, Chen L, Hanson BM, Yu Y, Liu Z, et al. Clinical outcomes and bacterial characteristics of carbapenem-resistant *Klebsiella pneumoniae* complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study. *The Lancet Infectious Diseases*. 2022 Mar;22(3):401–12.
  136. Falcone M, Bassetti M, Tiseo G, Giordano C, Nencini E, Russo A, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing *Klebsiella pneumoniae*. *Crit Care*. 2020 Dec;24(1):29.
  137. Li Y, Guo J, Yang H, Li H, Shen Y, Zhang D. Comparison of culture-negative and culture-positive sepsis or septic shock: a systematic review and meta-analysis. *Crit Care*. 2021;25(1).
  138. Jafari-Sales A, Al-Khafaji NSK, Al-Dahmashi HOM, Sadeghi Deylamdeh Z, Akrami S, Shariat A, et al. Occurrence of some common carbapenemase genes in carbapenem-resistant *Klebsiella pneumoniae* isolates collected from clinical samples in Tabriz, northwestern Iran. *BMC Res Notes*. 2023;16(1):311.
  139. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, Van Duin D, Clancy CJ. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum  $\beta$ -lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and *Pseudomonas aeruginosa* with Difficult-to-Treat Resistance (DTR- *P. aeruginosa* ). *Clinical Infectious Diseases*. 2022;75(2):187–212.
  140. Antequera A, Lopez-Alcalde J, Stallings E, Muriel A, Fernández Félix B, Del Campo R, et al. Sex as a prognostic factor for mortality in critically ill adults with sepsis: a systematic review and meta-analysis. *BMJ Open*. 2021 Sep;11(9):e048982.
  141. Tsang G, Insel MB, Weis JM, Morgan MAM, Gough MS, Frasier LM, et al. Bioavailable estradiol concentrations are elevated and predict mortality in septic patients: a prospective cohort study. *Crit Care*. 2016;20(1):335.
  142. Thompson KJ, Finfer SR, Woodward M, Leong RNF, Liu B. Sex differences in sepsis hospitalisations and outcomes in older women and men: A prospective cohort study. *Journal of Infection*. 2022;84(6):770–6.
  143. Lakbar I, Einav S, Lalevée N, Martin-Loeches I, Pastene B, Leone M. Interactions between Gender and Sepsis—Implications for the Future. *Microorganisms*. 2023;11(3):746.
  144. Wanrooij VHM, Cobussen M, Stoffers J, Buijs J, Bergmans DCJJ, Zelis N, et al. Sex differences in clinical presentation and mortality in emergency department patients with sepsis. *Annals of Medicine*. 2023;55(2):2244873.
  145. Wardi G, Tainter CR, Ramnath VR, Brennan JJ, Tolia V, Castillo EM, et al. Age-related incidence and outcomes of sepsis in California, 2008–2015. *Journal*

- of Critical Care. 2021;62:212–7.
146. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet*. 2020;395(10219):200–11.
  147. He W, Yao C, Wang K, Duan Z, Wang S, Xie L. Single-cell landscape of immunological responses in elderly patients with sepsis. *Immun Ageing*. 2024;21(1):40.
  148. Liu Z, Liang Q, Ren Y, Guo C, Ge X, Wang L, et al. Immunosenescence: molecular mechanisms and diseases. *Sig Transduct Target Ther*. 2023;8(1):200.
  149. Chiscano-Camón L, Ruiz-Sanmartin A, Bajaña I, Bastidas J, Lopez-Martinez R, Franco-Jarava C, et al. Current perspectives in the management of sepsis and septic shock. *Front Med*. 2024;11:1431791.
  150. Chen J, Zhang F, Liang L, Pan X, Zhang J, Jin G. Impact of underweight status on mortality in sepsis patients: a meta-analysis. *Front Med*. 2025;12:1549709. Available from:
  151. Bai L, Huang J, Wang D, Zhu D, Zhao Q, Li T, et al. Association of body mass index with mortality of sepsis or septic shock: an updated meta-analysis. *j intensive care*. 2023;11(1):27.
  152. Yeo HJ, Kim TH, Jang JH, Jeon K, Oh DK, Park MH, et al. Obesity Paradox and Functional Outcomes in Sepsis: A Multicenter Prospective Study. *Critical Care Medicine*. 2023;51(6):742–52.
  153. Wang X, Liu Y, Ding Y, Li M, Gao Y, Li T. Disease spectrum of patients with hospital-acquired multidrug-resistant organism infections in the intensive care unit: a retrospective study. *Front Microbiol*. 2025;16:1568615.
  154. Garvey M. Hospital Acquired Sepsis, Disease Prevalence, and Recent Advances in Sepsis Mitigation. *Pathogens*. 2024;13(6):461.
  155. Oami T, Imaeda T, Nakada T, Abe T, Takahashi N, Yamao Y, et al. Mortality analysis among sepsis patients in and out of intensive care units using the Japanese nationwide medical claims database: a study by the Japan Sepsis Alliance study group. *j intensive care*. 2023;11(1):2.
  156. Hu Q, Chen J, Sun S, Deng S. Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review. *IDR*. 2022;15:6907–26.
  157. Johnson MT, Reichley R, Hoppe-Bauer J, Dunne WM, Micek S, Kollef M. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis\*: *Critical Care Medicine*. 2011;39(8):1859–65.
  158. Gach MW, Lazarus G, Simadibrata DM, Sinto R, Saharman YR, Limato R, et al. Antimicrobial resistance among common bacterial pathogens in Indonesia: a systematic review. *The Lancet Regional Health - Southeast Asia*. 2024;26:100414.
  159. Aliska G, Utami WN. The Relationship Between Appropriateness of Antibiotic Use Based on the Gyssens Algorithm and Mortality: A Retrospective Cohort Study in Indonesian Tertiary Hospital. *Acta Med Indones*. 2024;56(2).
  160. Tićac M, Grubić Kezele T, Bubonja Šonje M. Impact of Appropriate Empirical

- Antibiotic Treatment on the Clinical Response of Septic Patients in Intensive Care Unit: A Single-Center Observational Study. *Antibiotics*. 2024;13(6):569.
161. Strich JR, Heil EL, Masur H. Considerations for Empiric Antimicrobial Therapy in Sepsis and Septic Shock in an Era of Antimicrobial Resistance. *The Journal of Infectious Diseases*. 2020;222(2):S119–31.
  162. Pattolath A, Adhikari P, Pai V. Carbapenemase-Producing *Klebsiella pneumoniae* Infections in Diabetic and Nondiabetic Hospitalized Patients. *Cureus*. 2024;16(1)
  163. Du Q, Yin X, Zhao H, Li J, Zhang J. Association between comorbid diabetes mellitus and mortality of patients with sepsis: A meta-analysis. *Int J Diabetes Dev Ctries*. 2024;44(1):128–36.
  164. Wang Z, Ren J, Wang G, Liu Q, Guo K, Li J. Association Between Diabetes Mellitus and Outcomes of Patients with Sepsis: A Meta-Analysis. *Med Sci Monit*. 2017;23:3546–55.
  165. Elkind MSV, Boehme AK, Smith CJ, Meisel A, Buckwalter MS. Infection as a Stroke Risk Factor and Determinant of Outcome After Stroke. *Stroke*. 2020;51(10):3156–68.
  166. Boehme AK, Ranawat P, Luna J, Kamel H, Elkind MSV. Risk of Acute Stroke After Hospitalization for Sepsis: A Case-Crossover Study. *Stroke*. 2017 Mar;48(3):574–80.
  167. Arero AG, Vasheghani-Farahani A, Tigabu BM, Arero G, Ayene BY, Soltani D. Long-term risk and predictors of cerebrovascular events following sepsis hospitalization: A systematic review and meta-analysis. *Front Med [Internet]*. 2022;9:1065476.
  168. Zaid Y, Rajeh A, Hosseini Teshnizi S, Alqarn A, Tarkesh F, Esmaeilinezhad Z, et al. Epidemiologic features and risk factors of sepsis in ischemic stroke patients admitted to intensive care: A prospective cohort study. *Journal of Clinical Neuroscience*. 2019;69:245–9.
  169. Ou SM, Lee KH, Tsai MT, Tseng WC, Chu YC, Tarng DC. Sepsis and the Risks of Long-Term Renal Adverse Outcomes in Patients With Chronic Kidney Disease. *Front Med*. 2022;9:809292.
  170. Berger B, Gumbinger C, Steiner T, Sykora M. Epidemiologic features, risk factors, and outcome of sepsis in stroke patients treated on a neurologic intensive care unit. *Journal of Critical Care*. 2014;29(2):241–8.
  171. Kong ZX, N. Karunakaran R, Abdul Jabar K, Ponnampalavanar S, Chong CW, Teh CSJ. A retrospective study on molecular epidemiology trends of carbapenem resistant Enterobacteriaceae in a teaching hospital in Malaysia. *PeerJ*. 2022;10:e12830.
  172. Saharman YR, Sania N, Aditianingsih D. Analysis Xpert® -Carba-R on Carbapenem Resistant Enterobacterales Screening in Intensive Care Unit in National Referral Hospital in Jakarta. *J Indon Med Assoc*. 2024;74(5):256–64.
  173. Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Front Cell Infect Microbiol*. 2020;10:314.

174. Kamalakar S, Rameshkumar MR, Lakshmi Jyothi T, Sundaramurthy R, Senthamilselvan B, Nishanth A, et al. Molecular detection of blaNDM and blaOXA-48 genes in Carbapenem-Resistant *Klebsiella pneumoniae* isolates from a tertiary care hospital. *Journal of King Saud University - Science*. 2024 ;36(7):103233.
175. Jayathilaka N, Shehana S, Nakkawita D, Senaratne T. Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis. *Syst Rev*. 2025;14(1):123.
176. Martínez-Zavaleta MG, Fernández-Rodríguez D, Hernández-Durán M, Colín-Castro CA, De Lourdes García-Hernández M, Becerra-Lobato N, et al. Acquired blaVIM and blaGES Carbapenemase-Encoding Genes in *Pseudomonas aeruginosa*: A Seven-Year Survey Highlighting an Increasing Epidemiological Threat. *Pathogens*. 2023;12(10):1256.
177. Pourrahim S, Rabbani M, Shokri D, Mansouvar Z. Antibiotics Resistenace Pattern and Carbapenemase Genes Distribution of *Klebsiella pneumonia* in Iran : A Review Article. 2024;13(52): 25-34
178. Aghamohammad S, Khazani Asforooshani M, Malek Mohammadi Y, Sholeh M, Badmasti F. Decoding the genetic structure of conjugative plasmids in international clones of *Klebsiella pneumoniae*: A deep dive into blaKPC, blaNDM, blaOXA-48, and blaGES genes. Al-Marzooq F, editor. *PLoS ONE*. 2023;18(11):e0292288.
179. Yuan Y, Lu Y, Cao L, Fu Y, Li Y, Zhang L. Genetic characteristics of clinical carbapenem-resistant *Klebsiella pneumoniae*: epidemic ST11 KPC-2-producing strains and non-negligible NDM-5-producing strains with diverse STs. *Sci Rep*. 2024;14(1):24296.
180. Cañada-García JE, Moure Z, Sola-Campoy PJ, Delgado-Valverde M, Cano ME, Gijón D, et al. CARB-ES-19 Multicenter Study of Carbapenemase-Producing *Klebsiella pneumoniae* and *Escherichia coli* From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3. *Front Microbiol*. 2022;13:918362.
181. Chen L, Mathema B, Chavda KD, DeLeo FR, Bonomo RA, Kreiswirth BN. Carbapenemase-producing *Klebsiella pneumoniae*: molecular and genetic decoding. *Trends in Microbiology*. 2014;22(12):686–96.
182. Wyres KL, Lam MMC, Holt KE. Population genomics of *Klebsiella pneumoniae*. *Nat Rev Microbiol*. 2020;18(6):344–59.
183. Kishi R, Nakano R, Nakano A, Harimoto T, Taniguchi R, Ando S, et al. Prevalence of carbapenem-resistant Enterobacterales with bla IMP-6 predominance in hospitals from 2018 to 2021 in Nara, Japan. *JAC-Antimicrobial Resistance*. 2024;6(4):dlae135.
184. Alvisi G, Curtoni A, Fonnesu R, Piazza A, Signoretto C, Piccinini G, et al. Epidemiology and Genetic Traits of Carbapenemase-Producing Enterobacterales: A Global Threat to Human Health. *Antibiotics*. 2025;14(2):141.
185. Saharman YR, Pelegrin AC, Karuniawati A, Sedono R, Aditianingsih D, Goessens WHF, et al. Epidemiology and characterisation of carbapenem-non-

- susceptible *Pseudomonas aeruginosa* in a large intensive care unit in Jakarta, Indonesia. *International Journal of Antimicrobial Agents*. 2019;54(5):655–60.
186. Darby EM, Trampari E, Siasat P, Gaya MS, Alav I, Webber MA, et al. Author Correction: Molecular mechanisms of antibiotic resistance revisited. *Nat Rev Microbiol*. 2024;22(4):255–255.
  187. Aiesh BM, Maali Y, Qandeel F, Omarya S, Taha SA, Sholi S, et al. Epidemiology and clinical characteristics of patients with carbapenem-resistant enterobacterales infections: experience from a large tertiary care center in a developing country. *BMC Infect Dis*. 2023;23(1):644.
  188. Rodrigues D, Baldissera GS, Mathos D, Sartori A, Zavascki AP, Rigatto MH. Amikacin for the treatment of carbapenem-resistant *Klebsiella pneumoniae* infections: clinical efficacy and toxicity. *Braz J Microbiol* [Internet]. 2021;52(4):1913–9.
  189. Wu D, Xiao J, Ding J, Jia Y, Guo Z, Liu H, et al. Predictors of Mortality and Drug Resistance Among Carbapenem-Resistant Enterobacteriaceae-Infected Pancreatic Necrosis Patients. *Infect Dis Ther*. 2021;10(3):1665–76.
  190. Wu X, Li X, Yu J, Fan C, Shen M, Li X. Investigation of in vitro susceptibility and resistance mechanisms to amikacin among diverse carbapenemase-producing Enterobacteriaceae. *BMC Med Genomics*. 2024;17(1):240.
  191. Yoon EJ, Jeong SH. Mobile Carbapenemase Genes in *Pseudomonas aeruginosa*. *Front Microbiol*. 2021;12:614058.
  192. Bush K. Past, present, and future perspectives on aztreonam and avibactam. *Expert Review of Anti-infective Therapy*. 2025;23(5):277–90.
  193. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. *Clinical Infectious Diseases*. 2024;
  194. Chirabhundhu N, Luk-In S, Phuadraksa T, Wichit S, Chatsuwan T, Wannigama DL, et al. Occurrence and mechanisms of tigecycline resistance in carbapenem- and colistin-resistant *Klebsiella pneumoniae* in Thailand. *Sci Rep*. 2024;14(1):5215.
  195. Li X, Chen S, Lu Y, Shen W, Wang W, Gao J, et al. Molecular epidemiology and genetic dynamics of carbapenem-resistant hypervirulent *Klebsiella pneumoniae* in China. *Front Cell Infect Microbiol*. 2025;15:1529929.
  196. Zhang Y, Zhang N, Wang M, Luo M, Peng Y, Li Z, et al. The prevalence and distribution of aminoglycoside resistance genes. *Biosafety and Health*. 2023;5(1):14–20.
  197. Costa A, Figueroa-Espinosa R, Gaudenzi F, Lincopan N, Fuga B, Ghiglione B, et al. Co-Occurrence of NDM-5 and RmtB in a Clinical Isolate of *Escherichia coli* Belonging to CC354 in Latin America. *Front Cell Infect Microbiol*. 2021;11:654852.
  198. Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam–avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. *Pharmacotherapy*. 2024;44(12):927–38.
  199. El-Badawy MF, Tawakol WM, El-Far SW, Maghrabi IA, Al-Ghamdi SA, Mansy MS, et al. Molecular Identification of Aminoglycoside-Modifying

- Enzymes and Plasmid-Mediated Quinolone Resistance Genes among *Klebsiella pneumoniae* Clinical Isolates Recovered from Egyptian Patients. *International Journal of Microbiology*. 2017;2017:1–12.
200. Ramachandran S, Deepak K, Shrikumaran M, Mohamed Rasiq R, Ananya S, Aruna V, et al. Unveiling Meropenem Resistance and Co-Resistance Patterns in *Klebsiella pneumoniae* and *Acinetobacter baumannii* : A Global Genome Analysis Using ML/DL and Association Mining. 2025-2
  201. Altayb HN, Elbadawi HS, Alzahrani FA, Baothman O, Kazmi I, Nadeem MS, et al. Co-Occurrence of  $\beta$ -Lactam and Aminoglycoside Resistance Determinants among Clinical and Environmental Isolates of *Klebsiella pneumoniae* and *Escherichia coli*: A Genomic Approach. *Pharmaceuticals*. 2022;15(8):1011.
  202. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. *Clinical Infectious Diseases*. 2019 ;69(Supplement\_7):S565–75.
  203. Yaghoubi S, Zekiy AO, Krutova M, Gholami M, Kouhsari E, Sholeh M, et al. Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review. *Eur J Clin Microbiol Infect Dis*. 2022;41(7):1003–22.
  204. Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. *Front Cell Infect Microbiol*. 2020;10:314.
  205. Lazar DS, Nica M, Dascalu A, Oprisan C, Albu O, Codreanu DR, et al. Carbapenem-Resistant NDM and OXA-48-like Producing *K. pneumoniae*: From Menacing Superbug to a Mundane Bacteria; A Retrospective Study in a Romanian Tertiary Hospital. *Antibiotics*. 2024;13(5):435.
  206. Stewart A, Harris P, Henderson A, Paterson D. Treatment of Infections by OXA-48-Producing Enterobacteriaceae. *Antimicrob Agents Chemother*. 2018;62(11):e01195-18.
  207. Abdelaziz SM, Aboshanab KM, Yahia IS, Yassien MA, Hassouna NA. Correlation between the Antibiotic Resistance Genes and Susceptibility to Antibiotics among the Carbapenem-Resistant Gram-Negative Pathogens. *Antibiotics*. 2021;10(3):255.
  208. Witt L, Babike A, Smith G, Satola S, Sexton ME, Jacob J. Carbapenemase genes and mortality in patients with carbapenem-resistant Enterobacterales, Atlanta, Georgia, 2011–2020. *ASHE*. 2023;3:s12–3.
  209. Chen WK, Yang Y, Tan BH. Increased Mortality Among Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Carriers Who Developed Clinical Isolates of Another Genotype. *Open Forum Infectious Diseases*. 2019;6(2):ofz006.
  210. Zhao S, Kennedy S, Perry MR, Wilson J, Chase-Topping M, Anderson E, et al. Epidemiology of and risk factors for mortality due to carbapenemase-producing organisms (CPO) in healthcare facilities. *Journal of Hospital Infection*. 2021;110:184–93.
  211. Deng S, Chen J, Zhou P, Hu Q. Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens

- Optimization: a real-world retrospective study in China. *BMC Infect Dis.* 2025;25(1):110.
212. European Centre for Disease Prevention and Control. Emergence of hypervirulent *Klebsiella pneumoniae* ST23 carrying carbapenemase genes in EU/EEA countries, first update. LU: Publications Office; 2021:17
213. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, et al. Global epidemiology and clinical outcomes of carbapenem-resistant *Pseudomonas aeruginosa* and associated carbapenemases (POP): a prospective cohort study. *The Lancet Microbe.* 2023;4(3):e159–70.

